Context Therapeutics Inc. · NASDAQ:CNTX

Context Therapeutics — Investor Presentation (October 2023)

31 slides from Context Therapeutics's investor presentation, Oct 31, 2023

  1. Slide 1: Corporate Presentation: Advancing Medicines for Solid Tumors

    November 2023 Corporate Presentation Advancing Medicines for Solid Tumors

  2. Slide 2: Important Notice and Disclaimers

    Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances

  3. Slide 3: Lead Program: CTIM-76, a Claudin 6 x CD3 Bispecific Antibody

    Lead Program: CTIM-76, a Claudin 6 x CD3 Bispecific Antibody Company Overview 3 CTIM-76 Claudin 6 x CD3 bispecific antibody • Selective for CLDN6: limited off-target effects • Potent: effective CLDN6-positive tumor killing at low doses • Wide therapeutic window: decreased risk of dangerous immune re

  4. Slide 4: CTIM-76: Claudin 6 x CD3 Bispecific Antibody

    CTIM-76: Claudin 6 x CD3 Bispecific Antibody Established bispecific format • Highly selective CLDN6 binding fragment antibody-binding (Fab) arm • Immunostimulatory CD3 binding single-chain fragment variable (scFv) domain is designed to be functionally monovalent to avoid aberrant T-cell activation,

  5. Slide 5: Bispecific Antibody T Cell Engagers in Solid Tumors

    Bispecific Antibody T Cell Engagers (bsAb TCE) in Solid Tumors CTIM-76 and other 2nd generation assets are addressing toxicity and dosing challenges associated with 1st generation products Company Overview Context Therapeutics Inc. - November 20235 1 Data as of August 1, 2023 Over 50 TCE in Clinical

  6. Slide 6: Claudin-targeted Therapeutics are Gaining Momentum

    Claudin-targeted Therapeutics are Gaining Momentum $263 million raised in 2023 for early-stage programs from TORL and Alentis Company Overview TORL Biotherapeutics (Private) Alentis Therapeutics (Private) Description Funding to advance TORL-1-23, a first-in-class, clinical- stage ADC targeting Claud

  7. Slide 7: Claudin-targeted Therapeutics are Gaining Momentum: Internal and competitor milestones

    Claudin-targeted Therapeutics are Gaining Momentum Internal and competitor milestones Company Overview Internal Milestone Competitor Milestones 7 November: CTIM-76 preclinical update at SITC conference Q1 2024: CTIM-76 IND filing October: TORL Biotherapeutics TORL-1-23 Phase 1 data update at ESMO co

  8. Slide 8: Claudin 6 (CLDN6) Target biology and therapeutic rationale

    Claudin 6 (CLDN6) Target biology and therapeutic rationale Context Therapeutics Inc. - November 20238

  9. Slide 9: CLDN6 is an Oncofetal Protein

    CLDN6 is an Oncofetal Protein Oncofetal proteins are considered favorable candidates for immunotherapy • Normally present at higher levels during embryonic development • Turned off or have low levels of expression in adult tissues • Increased expression known to occur in some tumor cells, including

  10. Slide 10: CLDN6 Has the Potential to Reach a Large Patient Population

    CLDN6 Has the Potential to Reach a Large Patient Population ~70,000 patients per year in the US only in Relapse/Refractory Setting CLDN6 Target Biology 10 Selected Cancer indications Incidence R/R Incidence CLDN6 Positive Patient Population Based on R/R Incidence Non-Small Cell Lung 201,229 110,653

  11. Slide 11: CLDN6 is Selectively Expressed on Cancer Cells

    CLDN6 is Selectively Expressed on Cancer Cells CLDN6 Target Biology Context Therapeutics Inc. - November 202311 (a) adrenal gland, (b) fallopian tube, (c) kidney, (d) liver, (e) thyroid, (f) prostate, (g) esophagus, (h) stomach, (i) colon, (j) cerebrum, (k) cerebellum, (l) spinal cord. (m) thymus, (

  12. Slide 12: High CLDN6 Associated with a Worsened Prognosis in Cancer Patients

    High CLDN6 Associated with a Worsened Prognosis in Cancer Patients CLDN6 Target Biology Context Therapeutics Inc. - November 202312 Endometrial Cancer1 Overexpression of CLDN6 is associated with worse overall survival in endometrial cancer patients 1 Kojima, Cancers, 2020; 2 Zhang, Front. Cell Dev.

  13. Slide 13: CLDN6 Has Limited Overlap with Competing Drug Targets

    CLDN6 Has Limited Overlap with Competing Drug Targets in Solid Tumors CLDN6 Target Biology Context Therapeutics Inc. - November 202313 Bishop, AnalyzeR [Data Set] Accessed August 1, 2023 CLDN6 vs. TROP2 CLDN6 vs. NECTIN4 Respiratory Cancer Limited correlation with TROP2 and Nectin-4, no correlation

  14. Slide 14: CTIM-76 Claudin 6 x CD3 Development Candidate

    CTIM-76 Claudin 6 x CD3 Development Candidate Context Therapeutics Inc. - November 202314

  15. Slide 15: Developing a Highly Selective CLDN6 Antibody is Challenging

    Developing a Highly Selective CLDN6 Antibody is Challenging CTIM-76 Program Context Therapeutics Inc. - November 202315 CLDN9 CLDN6 CLDN4 CLDN3 CLDN5 CLDN8 CLDN17 CLDN2 CLDN14 CLDN20 CLDN7 CLDN1 CLDN19 CLDN34 CLDN12 CLDN23 CLDN16 CLDN24 CLDN22 CLDN25 CLDN18 CLDN11 CLDN15 CLDN10 • CLDN6 antigen is co

  16. Slide 16: CTIM-76 Exhibits Excellent Selectivity and Potency

    CTIM-76 Exhibits Excellent Selectivity and Potency CTIM-76 Program Context Therapeutics Inc. - November 202316 • CTIM-76 CLDN6 EC50 of 3.41 nM (binding) • CTIM-76 preferentially binds to CLDN6 over CLDN3/4/9 • CLDN3/4/6/9 were transiently transfected in HEK-293F cells (4:1 Target:GFP) CLDN6 Selectiv

  17. Slide 17: CTIM-76 Induces Specific Lysis

    CTIM-76 Induces Specific Lysis CTIM-76 showed potent and specific killing of even those cell lines with very low CLDN6 expression Context Therapeutics Inc. - November 202317 K562-CLDN6 OV90 HEK CLDN6 Expression High Medium Low CTIM-76 (EC50) 0.0004 nM 0.049 nM 2.79 nM OV90 Cell LineK562-CLDN6 Cell L

  18. Slide 18: CTIM-76 Exhibits Limited Activation of Free Cytokines

    CTIM-76 Program Context Therapeutics Inc. - November 202318 CTIM-76 Exhibits Limited Activation of Free Cytokines • Data supports potential to dose at levels that promote cancer cell killing but have manageable levels of free cytokine production, thereby potentially reducing the risk of cytokine rel

  19. Slide 19: CTIM-76 Inhibits Tumor Growth in a Mouse Xenograft Model

    CTIM-76 Inhibits Tumor Growth in a Mouse Xenograft Model CTIM-76 Program Context Therapeutics Inc. - November 202319 CTIM-76 induced regression of established subcutaneous OVCAR3 xenograft tumors • CTIM-76 effectively engaged systemically administered human PBMC cells to promote significant tumor re

  20. Slide 20: CTIM-76 Well Tolerated in Toxicology Study in Cynomolgus Monkeys

    CTIM-76 Program CTIM-76 was well tolerated in Toxicology Study in Cynomolgus Monkeys Context Therapeutics Inc. - November 202320 CTIM-76 is Cross-Reactive to Cynomolgus Monkey CLDN6 and CD3 ̶ Exhibited linear pharmacokinetics ̶ Supports weekly dosing in Phase 1 study ̶ Cmin above threshold required

  21. Slide 21: Competitive Landscape

    Competitive Landscape 21 Context Therapeutics Inc. - November 2023

  22. Slide 22: Few CLDN6 Programs Have Excellent CLDN6-Selectivity

    Few CLDN6 Programs Have Excellent CLDN6-Selectivity CTIM-76, TORL-1-23, and AMG-794 are selective for CLDN6 vs CLDN3, CLDN4, CLDN9 Competitive Landscape Context Therapeutics Inc. - November 202322 HEK-293F cells were transfected with human CLDN6, CLDN9, CLDN3, or CLDN4 and stained with the indicated

  23. Slide 23: TORL ADC Internalization Restricted to Cells with High Levels of CLDN6

    Competitive Landscape TORL ADC Internalization Restricted to Cells with High Levels of CLDN6 Context Therapeutics Inc. - November 202323 • TORL-1-23MAb internalizes in a cell line where CLDN6 is overexpressed • TORL-1-23MAb does not internalize in a cell line with moderate CLDN6 expression • TORL-1-

  24. Slide 24: TORL ADC Potency Requires High Levels of CLDN6

    TORL ADC Potency Requires High Levels of CLDN6 Competitive Landscape Context Therapeutics Inc. - November 202324 • TORL ADC may be best utilized in cancers that express high levels of CLDN6, including testicular and ovarian cancers • TORL ADC incorporates a functional Fc and is active in cells with

  25. Slide 25: CTIM-76 is a More Potent Inducer of Cytotoxicity than AMG-794

    -14 -12 -10 -8 -6 0 2,000 4,000 6,000 8,000 Log [bsAb] (M) [C yt ok in e] (p g/ m L) CTIM-76 is a More Potent Inducer of Cytotoxicity and T Cell Activation than AMG-794 Competitive Landscape Cytotoxicity in OV90 Cell Line Cytokine Activation IL-6 at 24 Hours 25 1 Pham et al, AMG-794, a Claudin 6-tar

  26. Slide 26: BNT211 and TORL-1-23 Phase 1 Data at ESMO 2023 and ASCO 2023

    BNT211 and TORL-1-23 Phase 1 Data at ESMO 2023 and ASCO 2023 Competitive Landscape Context Therapeutics Inc. - November 202326 BNT211 TORL-1-23 Conference ASCO ESMO ASCO ESMO Cutoff Date March 10, 2023 September 10, 2023 May 3, 2023 September 29, 2023 Patients (n) 19 (17 evaluable) Ovarian = 8 Testi

  27. Slide 27: CLDN6 Competitive Landscape

    CLDN6 Competitive Landscape1 Context Therapeutics Inc. - November 202327 Scalable Manufacturing Process Complex Manufacturing Process Potential / Disclosed Safety Liabilities Selectivity for CLDN6 vs CLDN3,4,9 Limited Information on Asset Limited Selectivity Deprioritized CLDN6-CAR-NK CAR-NK + IL7 F

  28. Slide 28: Corporate

    Corporate 28 Context Therapeutics Inc. - November 2023

  29. Slide 29: Experienced Leadership Team

    Corporate Experienced Leadership Team • Experienced team with deep oncology experience • Our CMO led the clinical development of multiple blockbuster drugs including Kisqali, Arimidex, and Afinitor • Our management team is supported by a Board with strong public company operating and governance expe

  30. Slide 30: Corporate Investment Highlights

    Corporate Investment Highlights (Nasdaq: CNTX) Solid Tumors Large Unmet Need Claudin 6 High-Value Target November SITC Poster Anticipated Late Q1 2024 IND filing Milestones Deep Domain Experience, Track Record of Success Strong Team Expected Cash Runway into late 2024 Financial Strength Context Ther

  31. Slide 31: Advancing Medicines for Solid Tumors

    Advancing Medicines for Solid Tumors © Context Therapeutics 2023

Context Therapeutics — Investor Presentation (October 2023) on 6ix